302  <i>In vivo</i> HSC engineering with VLPs generates lineage-restricted, multiplexed CAR-M, NK, and T cells to cooperatively mediate robust and durable solid tumor control in pre-clinical models

302 Figure 1 HSC engineering with VLP encoding lineage-specific HER2 CAR to generate CAR-M, NK, and T cells.The CAR payload is integrated in HSCs but only expressed when T/NK-restricted and myeloid (Myel)-restricted promoters are active in mature immune cells Abstracts